期刊文献+

脑梗死二级预防阿司匹林抵抗的研究 被引量:1

下载PDF
导出
摘要 目的:评价脑梗死患者阿司匹林抵抗(AR)发生的情况,分析其临床有关因素,探讨可能机制。方法:600例急性脑梗死患者,每日服用阿司匹林100mg,连服10d,抽取静脉血,分别用二磷酸腺苷(ADP)、花生四烯酸(AA)诱导做血小板聚集试验,检测最大血小板聚集率。结果:患者中AR发生率4.67%,阿司匹林半敏感(ASR)者占20.33%,其中阿司匹林抵抗与女性、高LDL血症和糖尿病有相关性。结论:AR在脑梗死患者中确实存在。服用阿司匹林预防脑血管病患者应进行血小板聚集率检查,明确是否达到治疗目的,如有抵抗应调换其他药物。
出处 《实用医学杂志》 CAS 北大核心 2009年第11期1802-1803,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献4

二级参考文献15

  • 1Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971,231:232~235.
  • 2Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trial of antiplatelet therapy-I: prevention of death,myocardial infarction,and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994,308:81~246.
  • 3Gum P A, Kottke-Marchant K, Poggio E D, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol, 2001,88:230~235.
  • 4Pappas J M, Westengard J C, Bull B S. Population variability in the effect of aspirin on platelet function:implications for clinical trials and therapy. Arch Pathol Lab Med, 1994,118:801~804.
  • 5Hennekens C H, Albert C M, Godfried S L, et al. Adjunctive drug therapy of acute myocardial infarction: evidence from clinical trials. N Engl J Med, 1996,335:1660~1667.
  • 6Gum P A, Kandice K M, Welsh P A, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 2003,41:961~965.
  • 7Alexander J H, Harrington R A, Tuttle R H, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. Am J Cardiol, 1999,83:1147~1151.
  • 8Eikelboom J W, Hirsh J, Weitz J I, et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002,105:1650~1655.
  • 9Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients:the heart outcomes prevention evaluation study investigators. N Engl J Med, 2000,342:154~160.
  • 10Jneid H, Bhatt D L, Corti R, et al. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med, 2003,163:1145~1153.

共引文献18

同被引文献8

  • 1Hclgason CM,Tortorice KL,Winkler SR,et al.Aspirin response and failure in cerebral infarction[J].Stroke,1993,24(3):345-350.
  • 2Helgason CM,Bolin KM,Hoff JA,et al.Development of aspirin resistance in persons with previous ischemic stroke[J].Stroke,1994,25(12):2331-2336.
  • 3Hankey GJ,Eikelboom JW.Aspirin resistance.May be a cause of recurrent ischemic vascular events in patients taking aspirin[J].BMJ,2004,328(7438):477-479.
  • 4Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events[J].Circulation,2002,105(14):1650-1655.
  • 5Lee PY,Chen WH,Ng W,et al.Low-dose aspirin increases aspirin resistance in patients with coronary artery disease[J].Am J Med,2005,118(7):723-727.
  • 6Bomstein NM,Karepov VG,Aronovich BD,et al.Failure of aspirin treatment after stroke[J].Stroke,1994,25(2):275-277.
  • 7Undas A,Sanak M,Musial J,et al.Platelet glycoprotein IIIa polymorphism,aspirin,and thrombin generation[J].Lancet,1999,353(9157):982-983.
  • 8Macchi L,Christiaens L,Bmbant S,et al.Resistance in vitro to low dose aspirin is associated with platelet PIAl(GPIIIa)polymorphism but not with C807T(GP Ia/IVa)and C-5T Kozak(GPlbalpha)polymorphisms[J].JAm Coil Cardiol,2003,42(6):1115-1119.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部